Latest Content

Virtual care's pre- and post-visit windows offer pharma marketers a more targeted, attentive audience than physical waiting rooms, new research shows, and most brands aren't capitalizing on it yet.

Vikram Anand explains how connected pharmacovigilance systems improve HCP and patient experiences, and why predictive, AI-driven intake is the next frontier for manufacturers.

Health care's real challenge isn't more data, it's activation. Arcadia's Sandy Leonard on turning real-world evidence into point-of-care action.

Cardinal Health's Michelle Britt discusses how independent pharmacies are expanding clinical services and leaning on distributor partnerships to meet evolving patient and community needs.

AMCP's Adam Colborn discusses survey findings on TrumpRx's six-month performance, examining payer skepticism about pricing claims and pharmacy access hurdles for patients.

EVERSANA's Vikram Anand explains how disconnected PV systems and manual safety processes can create commercial delays after FDA approval.

In coordination with the Centers for Medicare and Medicaid Services, 10 PBMs will surface TrumpRx cash prices in prescribers' benefit tools, PCMA announced.

JD Power's 2026 U.S. Pharmacy Study shows mail-order satisfaction climbing as brick-and-mortar retailers lose customer trust and perceived value.

In this week's Pharma Pulse, Trump nominates Heidi Overton to lead the FDA, EVERSANA expands its AI-powered commercialization platform into medical affairs and market research, Moderna and Merck's personalized mRNA cancer vaccine clears a landmark Phase 3 trial, and IAG Cargo expands its pharma cold chain network into Kuala Lumpur.

AI-enabled pharmacovigilance is becoming a commercial capability that protects product value and speeds evidence-based market access decisions.

Trump is expected to pick White House aide Dr. Heidi Overton to lead the FDA, pending Senate confirmation, as the agency works to rebuild industry trust.

IAG Cargo has added a Kuala Lumpur station to its Constant Climate network, its 13th in Asia-Pacific, as regional biologics and personalized medicine demand accelerates.

EVERSANA's Vikram Anand breaks down FDA data on complete response letters, showing how gaps in pharmacovigilance and safety readiness, not manufacturing alone, drive costly delays in drug commercialization.